Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BETRF NASDAQ:RANI NASDAQ:TELO OTCMKTS:ZOMDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.14+3.8%$0.07$0.03▼$0.15$22.20M0.2868,357 shs16,366 shsRANIRani Therapeutics$0.64-6.6%$0.87$0.39▼$3.87$79.53M0.781.02 million shs829,082 shsTELOTelomir Pharmaceuticals$1.24+0.9%$1.27$1.05▼$3.10$85.35M-0.25131,889 shs11,484 shsZOMDFZomedica$0.09+0.8%$0.10$0.04▼$0.16$85.94M1.341.20 million shs240,642 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma0.00%+1.30%+173.71%+224.02%+82.34%RANIRani Therapeutics0.00%-10.90%-9.59%-11.63%+6.71%TELOTelomir Pharmaceuticals0.00%-3.15%-2.38%-5.38%+6.03%ZOMDFZomedica0.00%-7.94%-12.56%-18.84%+116.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.14+3.8%$0.07$0.03▼$0.15$22.20M0.2868,357 shs16,366 shsRANIRani Therapeutics$0.64-6.6%$0.87$0.39▼$3.87$79.53M0.781.02 million shs829,082 shsTELOTelomir Pharmaceuticals$1.24+0.9%$1.27$1.05▼$3.10$85.35M-0.25131,889 shs11,484 shsZOMDFZomedica$0.09+0.8%$0.10$0.04▼$0.16$85.94M1.341.20 million shs240,642 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma0.00%+1.30%+173.71%+224.02%+82.34%RANIRani Therapeutics0.00%-10.90%-9.59%-11.63%+6.71%TELOTelomir Pharmaceuticals0.00%-3.15%-2.38%-5.38%+6.03%ZOMDFZomedica0.00%-7.94%-12.56%-18.84%+116.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBETRFBetterLife Pharma 0.00N/AN/AN/ARANIRani Therapeutics 2.60Moderate Buy$8.751,262.93% UpsideTELOTelomir Pharmaceuticals 2.00HoldN/AN/AZOMDFZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BETRF, ZOMDF, RANI, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.004/21/2026TELOTelomir Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/14/2026RANIRani Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBETRFBetterLife PharmaN/AN/AN/AN/A($0.03) per shareN/ARANIRani Therapeutics$3.17M25.10N/AN/A$0.34 per share1.89TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.17 per shareN/AZOMDFZomedica$32.03M2.68N/AN/A$0.12 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBETRFBetterLife Pharma-$1.07MN/AN/AN/AN/AN/AN/A-772.34%N/ARANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)TELOTelomir Pharmaceuticals-$10.41M-$0.29N/AN/AN/AN/A-201.23%-172.71%9/2/2026 (Estimated)ZOMDFZomedica-$81.86M-$0.02N/AN/AN/A-65.92%-19.20%-17.54%N/ALatest BETRF, ZOMDF, RANI, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026RANIRani Therapeutics-$0.05N/AN/AN/A$0.93 millionN/A5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/14/2026Q1 2026TELOTelomir Pharmaceuticals-$0.07-$0.03+$0.04-$0.03N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBETRFBetterLife PharmaN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/AZOMDFZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBETRFBetterLife PharmaN/A0.040.04RANIRani TherapeuticsN/A3.403.40TELOTelomir PharmaceuticalsN/A7.007.00ZOMDFZomedicaN/A7.016.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBETRFBetterLife Pharma0.01%RANIRani Therapeutics30.19%TELOTelomir PharmaceuticalsN/AZOMDFZomedica8.95%Insider OwnershipCompanyInsider OwnershipBETRFBetterLife Pharma34.77%RANIRani Therapeutics26.73%TELOTelomir PharmaceuticalsN/AZOMDFZomedica6.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBETRFBetterLife Pharma7161.79 million105.53 millionNot OptionableRANIRani Therapeutics110123.88 million90.77 millionOptionableTELOTelomir Pharmaceuticals168.78 millionN/AN/AZOMDFZomedica50979.95 million913.80 millionN/ABETRF, ZOMDF, RANI, and TELO HeadlinesRecent News About These CompaniesZomedica's Assisi Loop(R) Products Designated "Fear Free(R)" as Alliance to Advance Low Stress Care and Pet Wellbeing Continues with Fear Free, LLCJune 25, 2026 | accessnewswire.comAZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on June 26, 2026: The Five Pillars of Zomedica - Framework for Clinical Value and Shareholder ReturnsJune 10, 2026 | finanznachrichten.deZomedica Announces "Fourth Friday at Four" Webinar on June 26, 2026: The Five Pillars of Zomedica - Framework for Clinical Value and Shareholder ReturnsJune 10, 2026 | finance.yahoo.comZomedica Corp.: Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing AssociationMay 20, 2026 | finanznachrichten.deZomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing AssociationMay 20, 2026 | accessnewswire.comAZomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech MarketMay 14, 2026 | accessnewswire.comAZomedica Corp Ordinary Shares ZOMDFMay 8, 2026 | morningstar.comMZomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in LiquidityMay 6, 2026 | accessnewswire.comAZomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational ScaleApril 16, 2026 | accessnewswire.comAZomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) PlatformMarch 18, 2026 | accessnewswire.comAZomedica Corp.: Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% ...March 16, 2026 | finanznachrichten.deZomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in LiquidityMarch 16, 2026 | accessnewswire.comAZomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor WebinarMarch 10, 2026 | accessnewswire.comAZomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary PathologyFebruary 25, 2026 | accessnewswire.comAZomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation PipelineFebruary 5, 2026 | accessnewswire.comAZomedica Expands its TRUVIEW(R) Microscopy Platform with AI Diagnostic Interpretation, Growing its Market OpportunityJanuary 23, 2026 | accessnewswire.comAZomedica Corp.: Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal HealthJanuary 22, 2026 | finanznachrichten.deZomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal HealthJanuary 22, 2026 | accessnewswire.comAZomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven GrowthJanuary 14, 2026 | accessnewswire.comAZomedica Launches Next-Generation VETGuardian PLUS(TM) Monitor, Expanding Core Monitoring Platform in Growing Veterinary MarketDecember 30, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Penny Stocks Under $5 Backed by Real Revenue GrowthBy Chris Markoch | June 20, 2026Energy Fuels Just Made a Bold Bet on Rare Earth MagnetsBy Jeffrey Neal Johnson | June 25, 2026Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereBy Jeffrey Neal Johnson | June 26, 20263 ETFs Pairing Market-Beating Returns With High Dividend YieldsBy Nathan Reiff | June 27, 2026AI’s Power Problem Is Turning Nuclear Stocks Into a Bigger Market StoryBy Jeffrey Neal Johnson | June 19, 2026BETRF, ZOMDF, RANI, and TELO Company DescriptionsBetterLife Pharma OTCMKTS:BETRF$0.14 +0.01 (+3.78%) As of 11:25 AM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Rani Therapeutics NASDAQ:RANI$0.64 -0.05 (-6.58%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Telomir Pharmaceuticals NASDAQ:TELO$1.24 +0.01 (+0.89%) As of 12:23 PM Eastern This is a fair market value price provided by Massive. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Zomedica OTCMKTS:ZOMDF$0.09 +0.00 (+0.80%) As of 12:03 PM EasternZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain Analysts See Major Upside for These 5 Stocks MarketBeat Week in Review – 07/06 - 07/10 3 Overlooked Stocks Positioned for the Next Market Rotation Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
